Patents by Inventor Brooke Nicole Harmon

Brooke Nicole Harmon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11885793
    Abstract: The present disclosure relates to methods, apparatuses, and systems to measure one or more electrical signals from a cultured cell layer. In some embodiments, such electrical signals can be indicative of transport or lack of transport of an agent through the cell layer.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: January 30, 2024
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Ramdane Abdallah Harouaka, Michael Bartsch, Jennifer Lauren Schwedler, Brooke Nicole Harmon
  • Patent number: 11807877
    Abstract: The present invention relates, in part, to methods for detecting nuclease activity, such as the activity of Cas nucleases. Also described herein are compositions for conducting assays, as well as methods for conducting assays in the presence of test compounds.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: November 7, 2023
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Kyle Jeffrey Seamon, Brooke Nicole Harmon, Joseph S. Schoeniger, Yooli Kim Light
  • Patent number: 11564919
    Abstract: An in vitro assay was designed to measure the activity of the alphavirus non-structural protein 2 (nsP2), which is the viral protease and is required for viral replication. By taking advantage of fluorescence-resonance energy transfer between two proteins, a protease cleavage assay was generated. This was utilized for high-throughput screening of 40,000 small molecules. Inhibitors were validated using cell-based assays to measure alphavirus infection and cytotoxicity. Certain compounds were then characterized for anti-viral efficacy in various cell lines in numerous assays. Compounds were tested against Chikungunya virus, Venezuelan Equine Encephalitis virus, Rift Valley Fever virus, and Zika virus. Three compounds (compounds I, II, and III) showed pan-alphavirus anti-viral efficacy at concentrations that did not result in cell toxicity. An additional compound, structure IV, showed broad spectrum inhibition of all viruses tested.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: January 31, 2023
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Brooke Nicole Harmon, Oscar Negrete, Joseph S. Schoeniger, Edwin A. Saada
  • Patent number: 10624949
    Abstract: The present invention relates to methods for treating a disease, in which the disease arises from dysregulation of the Wnt signaling pathway. In some instances, the disease can be treated by administering a Wnt pathway inhibitory compound. In other instances, the method optionally includes conducting a genome-wide screening to determine one or more genes resulting in a reduced disease state and then identifying the gene(s) as being involved in the Wnt signaling pathway.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: April 21, 2020
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Oscar A. Negrete, Brooke Nicole Harmon